Abstract library

16 results for "interview".
#2789 The Patient Journey – Experience from Symptoms to Diagnosis among Patients with Small Intestinal Neuroendocrine Tumours (SINET)
Introduction: Patients with SINET often have diffuse symptoms delaying diagnosis. In a patient survey it was observed that 1/3 of NET patients had a time span to diagnosis of > 5 years, with a median of 52 months. Here we assess the patients’ experience during that time period.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Study Coordinato Kajsa Oberg Holgersson
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme
Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD PhD Jorge Hernando-Cubero
#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christine Merkel
#215 Nurse Evaluation of Long-acting Somatostatin Analogue Injection Devices: A Quantitative Study
Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumors and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Hannah Kurth
Authors: Adelman D, Burgess A, Davies P R, ...
#829 On the Benign Side of Malignancy: How Neuroendocrine Tumors are Experienced by Patients and Their Family Carers
Introduction: Neuroendocrine tumors (NETs) are rare, slow-growing neoplasia with variable clinical presentations. Due to their non-specific symptoms and a lack of diagnostic tools, late diagnosis is common. There is little research relating to NETs as experienced by both patients and family carers.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: ...none of the below
Presenting Author: Susanne Kall
Authors: Kall S, Spichiger E, Stoll H, ...
#849 Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Neuroendocrine Tumors and Diarrhea Not Adequately Controlled on Octreotide
Introduction: Telotristat etiprate (LX1606), an oral tryptophan hydroxylase (TPH) inhibitor, was recently evaluated in a dose-escalation (DE) study in patients (pts) with carcinoid tumors and diarrhea not adequately controlled on octreotide.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Dr. Matthew H Kulke
#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#1291 How Long Is the Piece of String? – How Patients Negotiate the Uncertainties of a NET Diagnosis
Introduction: NET Patient Interviews
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Dr David Wyld
Authors: Wyld D, Plage S, Burge M, Broom A, ...
Keywords: Interviews